BC
TENX icon

Broadfin Capital’s Tenax Therapeutics TENX Stock Holding History

Broadfin Capital’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-62
Closed -$3.84M – 62
2016
Q4 		$3.84M Hold
62
– – 0.43% 51
2016
Q3 		$4.56M Hold
62
– – 0.41% 56
2016
Q2 		$5.04M Hold
62
– – 0.49% 47
2016
Q1 		$4.04M Hold
62
– – 0.39% 55
2015
Q4 		$6.46M Hold
62
– – 0.4% 60
2015
Q3 		$5.91M Hold
62
– – 0.33% 64
2015
Q2 		$7.26M Hold
62
– – 0.39% 57
2015
Q1 		$6.42M Hold
62
– – 0.5% 54
2014
Q4 		$7.56M Hold
62
– – 0.66% 41
2014
Q3 		$7.74M Hold
62
– – 0.81% 39
2014
Q2 		$8.03M Buy
62
+31
+100% +$4.78M 0.78% 42
2014
Q1 		$5.51M Buy
+31
New +$6.14M 0.53% 46

Other funds holding TENX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Broadfin Capital's TENX Position: Q1 2017 in Review

Broadfin Capital sold out of Tenax Therapeutics (TENX) in Q1 2017, closing a stake of 62 shares — an estimated $3.84M sold.

Broadfin Capital first reported a position in TENX in Q1 2014 and held it in 12 quarters. The position peaked at $8.03M in Q2 2014. 11 funds tracked by Wall St. Rank hold TENX as of Q1 2017.

  • Broadfin Capital reported no remaining Tenax Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Broadfin Capital sold 62 Tenax Therapeutics shares in Q1 2017, an estimated $3.84M.
  • Broadfin Capital first reported a position in Tenax Therapeutics in Q1 2014 and held it in 12 quarters.
  • Broadfin Capital's Tenax Therapeutics position peaked at $8.03M in Q2 2014.
  • 11 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2017.

Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.